×
0 0 0 0 0 0 0 0
Stockreport

Novartis Pushes Its Endocrine Cancer Franchise To The Next Level [Seeking Alpha]

ADVANCED ACCELERATOR APPLICATIONS SA AMERICAN DE (AAAP)  More Company Research Source: Seeking Alpha
Last advanced accelerator applications sa american de earnings: 8/31 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: adacap.com/investor-relations
PDF Novartis Pushes Its Endocrine Cancer Franchise To The Next LevelSummaryNovartis snags FDA approval for Lutathera several months after acquiring Advanced Accelerator Applications.Peak sales for Lutathera are estimated to be around $2 billion.The FDA approval of Lutathera in neuroendocrine tumors should make up for the decline in sales for Afinitor.The acquisition of Advanced Accelerator Applications also gave Novartis other cancer indications as well like prostate cancer.Novartis is continuing to make good progress towards building its pipeline, especially after already having achieved a first in CAR-T approval for its therapy Kymriah. [Read more]

IMPACT SNAPSHOT EVENT TIME: AAAP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AAAP alerts
from News Quantified